Innovation Pharmaceuticals Inc (IPIX)

[biodoc]

I'm not sure what some of you were expecting but this appears to me as an incredibly strong validation of Kevetrin by one of the most credible leaders in oncology. With such a short half life and only weekly dosing, it's unrealistic to expect a cure or lasting impact at this stage. That will come when dosing is optimized. This poster is giving us many reasons to be extremely optimistic about Kevetrin. I think the discussions around the poster and presentation would make most of you smile. Wish I was a fly on the wall. On the road right now but I'll try to focus on details later.

"....Kevetrin can function as a major inducer of apoptosis in many types of tumors independent of p53 mutation status."